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Ambivalent Antihistamines
Warding off allergies with antihistamines
may prove to be dangerous for allergy suf-
ferers, if recent studies on mice are any
indication. The study found that three
widely used antihistamines stimulate tumor
growth in mice.
Lorne Brandes and colleagues at the
Manitoba Institute of Cell Biology at the
University of Manitoba in Winnipeg,
Canada, injected tumor culture lines into
mice and then administered antihistamines
daily in varying estimated human-equiva-
lent doses for 18-21 days. The researchers
then sacrificed the mice and surgically
removed the tumors. In comparing the
weights ofthe tumors, theyfound that three
of the five antihistamines tested caused the
tumors to grow heavier. This innovative
method differs from traditional tests for car-
cinogenicity, which involve administering a
substance to healthy laboratory animals; as a
result, the study-s conclu-
sions are being questioned.
The three antihista-
mines that were found to
cause the existing tumors
in the mice to grow larger
are loratadine, which is
used in Claritin, made by
Schering-Plough of Mad-
ison, New Jersey; astemi-
zole, the main ingredient
in Hismanal, made by
Janssen Pharmaceutica
Inc. of Titusville, New
Jersey; and hydroxyzine,
used in Atarax, made by
the Roerig Division of
Pfizer Inc. of New York.
Following the publication
of the study, the manu-
facturers of these drugs
issued statements defend-
ing their products and
criticizing the researchers'
human risk assessment
methods.
The two other drugs tested in the study
were cetrizine, which is used in Reactine,
also made by Pfizer, and doxylamine, used
in over-the-counter drugs such as NyQuil
and Unisom, which were not found to
stimulate tumor growth.
The researchers defend their methods in
the report of the study, saying, "Although
the potential for carcinogenicity has
received considerable attention in preclini-
cal drug testing in rodents, the propensity
of pharmaceuticals to enhance the growth
of existing tumors or the development of
malignancy induced by chemical or viral
initiators has been neglected."
The study was published in the 18 May
1994 issue of the Journal ofthe National
Cancer Institute along with an editorial
written by Douglas L. Weed, of the
Preventive Oncology Branch, Division of
Cancer Prevention and Control, of the
National Cancer Institute. Weed raised
questions about the human risk assessment
methods that were involved in the study
and called for further research, recom-
mending that no immediate changes be
made in the use ofthe antihistamines.
Brandes had called on the Food and
Drug Administration to change the labeling
on the antihistamines, but the FDA said
such a move would be premature. In a press
release, the agencysaid that standard carcino-
genicity tests with the antihistamines in mice
and rats do not demonstrate carcinogenicity
and the FDA believes that further study is
needed before any action is taken. The FDA
advised consumers that short term use ofthe
antihistamines is not at issue.
The agency is taking the study seriously,
however. Researchers at the FDA plan to
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duplicate the study and reevaluate the
human risk assessment methods. According
to Joseph DeGeorge, supervisory pharma-
cologist in the Division of Oncology and
Pulmonary Drug Products at the FDA,
researchers will not onlyduplicate the study,
but will extend their research to include
modifications to Brandes' work. For exam-
ple, DeGeorge said that human tumors may
different than the tumor types that Brandes
used. "We are trying to extend to other
tumor types and other assays." The FDA is
interacting very closely with Brandes in
duplicating hiswork, DeGeorge said.
The FDA will also examine another
innovative method used in Brandes' study
pertaining to how tumors respond to
increasing doses ofantihistamines. Brandes
found that the dose-response rate forms a
bell curve, with little response at low doses
and high doses, and heavy response at mid-
sized doses. In the past, researchers have
generally assumed that response increases
linearly as dose increases.
Brandes' finding implies that traditional
research involving only the administration
ofhigh doses could have missed high levels
ofresponse at mid-sized doses.
Meeting of the Cancer Minds
A recent meeting brought together scientists
conducting cancer research using informa-
tion gained from studies using species "rang-
ing from bacteria to yeast to fruit flies to
mice to humans," as described by Richard
Paules, coordinator of the conference on
Molecular Mechanisms of Environmental
Carcinogenesis. The meeting, held at the
NIEHS September 19-20, was a chance for
researchers from diverse areas to present the
most recent advancements in
environmental cancer reseach.
Perhaps the most exciting
and certainly the most publi-
cized information presented
at the conference was the iso-
lation of BRCA1, the gene
for inherited susceptibility to
breast cancer by a team of
researchers from several insti-
tutions including the NIEHS
and the University of Utah
School of Medicine. Several
other presentations high-
lighted recent advance in
cancer knowledge in such
areas as the varying conse-
quences ofgenetic damage in
animals with different genetic
backgrounds; the correlation
between the appearance of
Li-Fraumeni syndrome in
young children caused by
genetic mutations in the p53
gene and the appearance of
cancers from the same type of-mutations in
their parents and grandparents later in life;
identification of a mutation in an area of
chromosome 14q which may be developed
as a prognostic tool for endometrial cancer;
and an update on research of the effect of
exogenous estrogens on rates ofendometri-
al and breast cancers.
Researcher Amy Moser ofthe McArdle
Laboratory for Cancer Research at the
University of Wisconsin School of
Medicine presented studies supporting the
theory that particular genetic mutations, in
combination with particular environmen-
tal toxicants, may result in different conse-
quences; for example, mutations may pro-
duce a lot oftumors or no tumors depend-
ing on the genetic makeup of the individ-
ual in which they occur. Moser's studies
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